Cargando…

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome

The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome. This study included patients who admitted in Jiangxi Provincial People’s Hospital from January 1, 2017 to December 31, 2019 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Lan, Fu, Qianyu, Zhou, Longhua, Fan, Yuqin, Liu, Fenfen, Fan, Yuanyuan, Zhang, Xin, Lin, Weiqing, Wu, Xiaohe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688417/ https://www.ncbi.nlm.nih.gov/pubmed/34930986 http://dx.doi.org/10.1038/s41598-021-03773-z

Ejemplares similares

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
por: Fu, Qianyu, et al.
Publicado: (2023)

D-dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus
por: Cheng, Lan, et al.
Publicado: (2022)

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
por: Cheng, Lan, et al.
Publicado: (2022)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker, Catherine M, et al.
Publicado: (2016)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise
por: Nian, Hua, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Feng, Miao, et al.
Publicado: (2019)

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial
por: Zhang, Jiaqi, et al.
Publicado: (2022)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome
por: Song, Zhuo-ran, et al.
Publicado: (2022)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach
por: Satyam, Shakta Mani, et al.
Publicado: (2023)

FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control
por: Phadke, Dr Uday, et al.
Publicado: (2023)

Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019)

Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study
por: Tang, Yi, et al.
Publicado: (2019)

Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
por: Ng, Hwee-Yeong, et al.
Publicado: (2021)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
por: Yang, Young-Mo, et al.
Publicado: (2015)

Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality
por: Tizazu, Anteneh Mehari, et al.
Publicado: (2019)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
por: Chin, Ken Lee, et al.
Publicado: (2019)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Monotherapy of experimental metabolic syndrome: I. Efficacy and safety
por: Bezek, Štefan, et al.
Publicado: (2017)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lrrd7vhcidj55pnmeaoii6agp7